Protective effect of buflomedil in a rat model of moderate cerebral ischemia

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 8, 2005, Pages 437-442

  Briguglio, Francesco S ^a   Mondello, Maria Rita ^a   Galluzzo, Mariangela ^a   Raneri, Eugenio ^a   De Pasquale, Anna ^a   Saija, Antonella ^a   Trombetta, Domenico ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Buflomedil, postischemic cerebral damage, protective effect, rat; CAS 55837 25 7; Neuron specific enolase; Vasoactive drug

Indexed keywords

BUFLOMEDIL; LACTIC ACID; NEURON SPECIFIC ENOLASE; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CLAMP; ARTERY OCCLUSION; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN ISCHEMIA; BRAIN METABOLISM; CAROTID ARTERY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; ENERGY METABOLISM; ENZYME BLOOD LEVEL; HIPPOCAMPUS; LACTATE BLOOD LEVEL; MALE; NEUROPROTECTION; NONHUMAN; PYRAMIDAL NERVE CELL; RAT; RAT STRAIN; SMOOTH MUSCLE RELAXATION;

EID: 23944495565     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296885     Document Type: Article

References (32)

1. Clissold, S. P., Lynch, S., Sorkin, E. M., Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs. 33, 430 (1987)
2. Briguglio, E, Di Marco, V., Circosta, C. et al., Metabolic effects of buflomedil hydrochloride. J. Int. Med. Res. 13, 131 (1985)
3. Briguglio, F., Briguglio, E., Di Marco, V et al., Effects of buflomedil hydrochloride in occlusive arterial disease of the lower limbs stage IV. J. Int. Med. Res. 14, 115 (1986)
4. Boisseau, M. R., Pruvost, A., Renard, M. et al., Effect of buflomedil on the neutrophil-endothelial cell interaction under inflammatory and hypoxia conditions. Haemostasis 26 (Suppl. 4), 182 (1996)
5. Holzer, K., Thiel, M., Kreimeier, U. et al., Buflomedil hydrochloride reduces systemic activation of polymorphonuclear leukocytes during hyperdynamic endotoxemia. Shock 10, 335 (1998)
6. Redondo, E, Garcia-Foncillas, J., Espana, A. et al., Differential modulation of IL-8 and TNF-alpha expression in human keratinocytes by buflomedil chlorhydrate and pentoxifylline. Exp. Dermatol. 6, 186 (1997)
7. Ciuffetti, G., Mercuri, M., Lombardini, R. et al., Whole blood filterability in chronic cerebrovascular disorders: effects of the use of buflomedil hydrochloride. Minerva Med. 80, 1237 (1989)
8. Kobayashi, S., Yamaguchi, S., Okada, K. et al., Effect of long-term administration of buflomedil on regional cerebral blood flow in chronic cerebral infarction. Angiology 39, 934 (1988)
9. Karoutas, G., Milonas, I., Artemis. N. et al., The pharmacological effects of buflomedil in patients with multi-cerebral infarcts dementia: an open, preliminary assessment. Curr. Med. Res. Opin. 10, 380 (1987)
10. Cucinotta, D., Aveni Casacci, M. A., Pedrazzi, F. et al., Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin. J. Int. Med. Res. 20, 136 (1992)
11. Jansen, W., Bruckner, G. W., Jansen, P., The treatment of senile dementia associated with cerebrovascular insufficiency: a comparative study of buflomedil and dihydrogenated ergot alkaloids. J. Int. Med. Res. 13, 48 (1985)
12. Bossi, L., Buflomedil and nicergoline in the targeted treatment of acute cerebral ischemia. Randomized comparative double blind study. Minerva Med. 76, 1005 (1985)
13. Traystman, R. J., Animal models of focal and global cerebral ischemia. ILAR J. 44, 85 (2003)
14. Kunimatsu, T., Asai, S., Kanematsu, K. et al., Effects of glutamate receptor agonist on extracellular glutamate dynamics during moderate cerebral ischemia. Brain Res. 923, 178 (2001)
15. Fresta, M., Puglisi, G., Di Giacomo, C. et al., Liposomes as in-vivo carriers for citicoline: effects on rat cerebral postischaemic reperfusion. J. Pharm. Pharmacol. 46, 974 (1994)
16. Fresta, M., Wehrli, E., Pugliesi, G. et al., Enhanced therapeutic effect of cytidine-5′-diphosphate choline when associated with GM1 containing small liposomes as demonstrated in a rat ischemia model. Pharm. Res. 12, 1769 (1995)
17. nd ed., plate 31, Academic Press, Sydney (1986)
18. Bhardwaj, A., Alkayed, N. J., Kirsch, J. R. et al., Mechanisms of ischemic brain damage. Curr. Cardiol. Rep. 5, 160 (2003)
19. Endres, M., Dirnagl, U., Ischemia and stroke. Adv. Exp. Med. Biol. 513, 455 (2002)
20. Phan, T. G., Wright, P. M., Markus, R. et al., Salvaging the ischaemic penumbra: more than just reperfusion? Clin. Exp. Pharmacol. Physiol. 29, 1 (2002)
21. Murphy, J., Pharmacological treatment of acute ischemic stroke. Crit. Care Nurs. Q. 26, 276 (2003)
22. Madhavan, R., Chaturvedi, S., Transient ischaemic attacks: new approaches to management. CNS Drugs 17, 293 (2003)
23. Toni, D., Gallo, V., Falcou, A. et al., Treatment of cerebrovascular diseases: state of the art and perspectives. J. Cardiovasc. Pharmacol. 38, 283 (2001)
24. Barber, P. A., Auer, R. N., Buchan, A. M. et al., Understanding and managing ischemic stroke. Can. J. Physiol. Pharmacol. 79, 283 (2001)
25. Horn, M., Seger, F., Schlote, W., Neuron-specific enolase in gerbil brain and serum after transient cerebral-ischemia. Stroke 26, 290 (1995)
26. Schaarschmidt, H., Prange, H. W, Reiber, H. et al., Neuron-specific enolase concentrations in blood as a prognostic parameter in cerebrovascular diseases. Stroke 25, 558 (1994)
27. Cunningham, R. T., Watt, M., Winder, J. et al., Serum neurone-specific enolase as an indicator of stroke volume. Eur. J. Clin. Invest. 26, 298 (1996)
28. Schoerkhuber, W, Kittler, H., Sterz, F. et al., Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. Stroke. 30, 1598 (1999)
29. Ishikawa, T., Sano, T, Kuroda, Y. et al., Effects of buflomedil on survival rate, local cerebral blood flow and glucose utilization after cerebral ischemia in spontaneously hypertensive rats. Nippon Yakurigaku Zasshi. 90, 303 (1987)
30. Capecchi, P. L., Laghi Pasini, F., Sodi, N. et al., Increase in plasma levels of adenosine and adenine nucleotides after intravenous infusion of buflomedil in humans. J. Cardiovasc. Pharmacol. 25, 35 (1995)
31. Mathis, J. M., Jensen, M. E., Dion, J. E., Technical considerations on intra-arterial papaverine hydrochloride for cerebral vasospasm. Neuroradiology 39, 90 (1997)
32. Trombetta, D., Briguglio, F. S., Raneri, E. et al., Protective effect of buflomedil hydrochloride in rats with experimental cerebral ischemia. Pharmacol. Res. 43, 87 (2001)